Ligatech Bioscience

About Ligatech Bioscience

Established in 2014, Ligatech Bioscience is a Shanghai-based company specializing in the medical device sector with a focus on sports medicine. The firm is engaged in the research, development, manufacturing, and sale of products designed to address various joint injuries, positioning itself as a key domestic player in a market experiencing annual growth of over 20%. Ligatech provides a comprehensive range of solutions covering diagnosis, treatment, and exercise management, serving a client base that includes over 2,000 hospitals for its consumables and installations of small equipment in more than 200 hospitals.

The company's business model revolves around providing a full suite of products for sports-related medical procedures. Ligatech's product portfolio is extensive, featuring artificial ligaments, cruciate ligament fixation systems, meniscal repair systems, PEEK and metal wire anchors, high-strength non-absorbable medical sutures, and surgical traction frames. A significant achievement for the company was receiving the first domestic NMPA approval for an artificial ligament in China, a milestone that addressed a gap in the national market. Their offerings also include advanced diagnostic tools like a proprietary Digital Biplane X-ray Imaging System and active devices such as arthroscopy, shaver, and plasma surgical systems. The company holds over 160 patents and has obtained CE, ISO 13485, and NMPA certifications for its products.

Ligatech has demonstrated consistent growth and a strong ability to secure capital. Since its inception, the company has successfully completed multiple funding rounds, including a Series D financing in September 2023 that raised hundreds of millions of yuan, led by investors like XindaKunpeng and Legend Capital. This followed previous rounds, such as a CNY 314.8 million financing in April 2021. These financial infusions support the company's research and development efforts, which are carried out in collaboration with key sports medicine experts and universities, and its plans for overseas market expansion.